Evidence map›Paper›PMID 32987359›Full record

Trial reportParkinsonism & related disorders2020

Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study.

Kelly A Mills, Ruth B Schneider, Marie Saint-Hilaire, G Webster Ross, Robert A Hauser, Anthony E Lang, Matthew J Halverson, David Oakes, Shirley Eberly, Irene Litvan and 4 more

Open access · greenAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Parkinsonism & related disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 23 citations in OpenAlex.

  1. Subjective cognitive complaints in cognitively unimpaired Parkinson's disease: Associations with affective burden, motor severity, and awareness-related processes.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Long-term effects of anti-Frontiers in neurology · 2023
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 2 countries.

Kelly A MillsJohns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: kmills16@jhmi.edu.
Ruth B SchneiderUniversity of Rochester School of Medicine and Density, Rochester, NY, USA.
Marie Saint-HilaireBoston University School of Medicine, Boston, MA, USA.
G Webster RossVA Pacific Islands Health Care System, Honolulu, HI, USA.
Robert A HauserUniversity of South Florida Morsani College of Medicine, Tampa, FL, USA.
Anthony E LangEdmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, UHN, Division of Neurology, University of Toronto, Toronto, ON, Canada.
Matthew J HalversonThe University of Utah School of Medicine, East Salt Lake City, UT, USA.
David OakesUniversity of Rochester School of Medicine and Density, Rochester, NY, USA.
Shirley EberlyUniversity of Rochester School of Medicine and Density, Rochester, NY, USA.
Irene LitvanUniversity of California San Diego, La Jolla, CA, USA.
Karen BlindauerMedical College of Wisconsin, Milwaukee, WI, USA.
Camila AquinoUniversity of Calgary, Calgary, AB, Canada.
Tanya SimuniNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Connie MarrasEdmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, UHN, Division of Neurology, University of Toronto, Toronto, ON, Canada.
University of Rochester · USJohns Hopkins Medicine · USMedical College of Wisconsin · USNorthwestern University · USToronto Western Hospital · CAUniversity of Calgary · CAUniversity of California, San Diego · USUniversity of South Florida · USUniversity of Toronto · CAUniversity of Utah · USVA Pacific Islands Health Care System · US

Funding

Clinical Coordination Center for STEADY-PD3U01NS080818 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SIMUNI, TANYA · 2014 to 2018
$13.0M
Data Coordination Center for STEADY-PD3U01NS080840 · NINDS · UNIVERSITY OF ROCHESTER · PI HOLLOWAY, ROBERT G. · 2014 to 2018
$8.6M
NINDS NIH HHS U01 NS080818NINDS NIH HHS U01 NS080840
6 · The paper itself

Abstract

backgroundCognitive decline creates substantial morbidity and cost in Parkinson's disease (PD) and clinicians have limited tools for counseling patients on prognosis. We aimed to use data from a randomized, controlled trial of isradipine in Parkinson's disease (STEADY-PD III) to determine which objective cognitive domain deficits drive patient complaints of cognitive symptoms.

methodsNeuro-Quality of Life (Neuro-QoL) Cognition: General Concerns (GC), and Cognition: Executive Function (EF) (subjective measures), were administered at baseline, 1, 2, and 3 years in 324 people with PD. Baseline Montreal Cognitive Assessment (MoCA) was divided into 4 domains: visuospatial/executive, memory, attention, and language (objective measures). Spearman rank correlations and multiple regression models adjusted for other clinical variables evaluated associations between baseline Neuro-QoL domains and individual MoCA domains. Multiple regression models evaluated the association between baseline MoCA domain performance and Neuro-QoL change over three years. Cox proportional hazards predicted development of PD-MCI based on baseline and time-varying Neuro-QoL reporting.

resultsHigher MoCA memory performance was associated with better Neuro-QoL-GC (β = 0.75, SE = 0.391, p = 0.05) and Neuro-QoL-EF (β = 0.81, SE = 0.36, p = 0.02) at baseline. There was a trend for baseline MoCA memory to predict the degree of subjective cognitive decline on the Neuro-QoL-EF (β = 0.70, SE = 0.42, p = 0.09). Baseline depression and anticholinergic use were associated with worsened Neuro-QoL-EF and Neuro-QoL-GC. Increasing subjective cognitive complaints in Neuro-QoL-EF were associated with development of PD-MCI over 3 years of follow-up (HR = 0.95, CI = 0.90-1.0, p = 0.039).

conclusionsObjective memory impairment may be a stronger predictor than executive or visuospatial dysfunction for the presence of subjective cognitive complaints in early PD.

Indexed as

Patient Reported Outcome MeasuresAgedCalcium Channel BlockersCognitive DysfunctionDepressionDiagnostic Self EvaluationExecutive FunctionFemaleHumansIsradipineLongitudinal StudiesMaleMiddle AgedParkinson DiseaseQuality of LifeCalcium Channel BlockersIsradipineCognitive impairmentParkinson's diseasePatient-reported outcomes

Identifiers

PMID32987359
PMCPMC12396391
OpenAlexW3088665406

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.